Silence to Merge with Intradigm in Bid to Create Top RNAi Drug, Delivery Player

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories